Breaking News Instant updates and real-time market news.

2021-01-27 14:03:02 APPS Digital Turbine $60.91 / -1.09 (-1.76%) 14:03 01/27/21 01/27 14:03 01/27/21 14:03	Digital Turbine price target raised to $70 from $42 at Roth Capital Roth Capital analyst Darren Aftahi raised the firm's price target on Digital Turbine to $70 from $42, stating that Google Play download data continued to show increased mobile adoption in Q4 along with signs that the broader advertising market was "very healthy" in the quarter. The analyst, whose checks point to "outsized gains" from e-commerce apps this holiday season along with continued streaming download strength, keeps a Buy rating on Digital Turbine shares.	03 Feb
APPS Digital Turbine $60.91 / -1.09 (-1.76%) 01/22/21 Maxim Digital Turbine initiated with a Buy at Maxim 12/21/20 Canaccord Digital Turbine downgraded to Hold from Buy at Canaccord 12/17/20 Craig-Hallum Digital Turbine price target raised to $60 from $44 at Craig-Hallum 11/18/20 Craig-Hallum Digital Turbine price target raised to $44 from $38 at Craig-Hallum

2021-01-27 14:03:02

APPS

Digital Turbine

$60.91 / -1.09 (-1.76%)

14:03

01/27/21

01/27

14:03

01/27/21

14:03

Digital Turbine price target raised to $70 from $42 at Roth Capital

Roth Capital analyst Darren Aftahi raised the firm's price target on Digital Turbine to $70 from $42, stating that Google Play download data continued to show increased mobile adoption in Q4 along with signs that the broader advertising market was "very healthy" in the quarter. The analyst, whose checks point to "outsized gains" from e-commerce apps this holiday season along with continued streaming download strength, keeps a Buy rating on Digital Turbine shares.

03
Feb

APPS Digital Turbine

$60.91 / -1.09 (-1.76%)

01/22/21 Maxim: Digital Turbine initiated with a Buy at Maxim

12/21/20 Canaccord: Digital Turbine downgraded to Hold from Buy at Canaccord

12/17/20 Craig-Hallum: Digital Turbine price target raised to $60 from $44 at Craig-Hallum

11/18/20 Craig-Hallum: Digital Turbine price target raised to $44 from $38 at Craig-Hallum

TODAY'S FREE FLY STORIES

Hot Stocks	CureVac and Novartis in initial pact on Covid vaccine candidate » 07:31 03/04/21 03/04 07:31 03/04/21 07:31 CVAC CureVac $83.44 / -9.76 (-10.47%) , NVS Novartis $84.16 / -0.635 (-0.75%) CureVac (CVAC) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 02/05/21 CureVac enters pact with UK Government to develop SARS-CoV-2 variant vaccine 02/04/21 CureVac expands CV8102 cancer program to advanced melanoma 02/03/21 CureVac, GSK in pact to jointly develop mRNA vaccines for COVID-19 01/07/21 Bayer signs collaboration, services agreement with CureVac for COVID-19 vaccine NVS Novartis $84.16 / -0.635 (-0.75%) 03/02/21 Novartis shareholders approve 1.7% increase in dividend to CHF 3.00 per share 03/01/21 Homology Medicines regains worldwide rights to ophthalmology program 02/17/21 Novartis announces SCD grant agreement with Bill & Melinda Gates Foundation 02/16/21 Novartis reports Entresto granted expanded indication in chronic heart failure CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/07/21 Morgan Stanley CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley 12/10/20 Credit Suisse CureVac downgraded to Underperform on rising valuation at Credit Suisse 12/10/20 Credit Suisse CureVac downgraded to Underperform from Neutral at Credit Suisse 11/02/20 Piper Sandler CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper NVS Novartis $84.16 / -0.635 (-0.75%) 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer 02/02/21 Morgan Stanley Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley 02/01/21 Truist iRhythm price target lowered to $220 from $265 at Truist 02/01/21 Cowen Novartis downgraded to Market Perform after 'tepid' guidance at Cowen NVS NVS Novartis $84.16 / -0.635 (-0.75%) 01/26/21 Novartis sees 2021 core operating income to grow mid single digit 01/26/21 Novartis reports Q4 core EPS $1.34, consensus $1.36 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 28 Jan 14 Aug CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/06/21 CureVac, Bayer reach alliance deal over COVID-19 vaccine, Reuters says 09/04/20 Germany awards grant to CureVac to accelerate vaccine development, BI reports NVS Novartis $84.16 / -0.635 (-0.75%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports CVAC NVS CVAC CureVac $83.44 / -9.76 (-10.47%) 01/25/21 Fly Intel: After-Hours Movers 01/07/21 Fly Intel: Pre-market Movers 11/10/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: Pre-market Movers NVS Novartis $84.16 / -0.635 (-0.75%) 02/11/21 Fly Intel: Wall Street's top stories for Thursday 02/11/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks CVAC CVAC CureVac $83.44 / -9.76 (-10.47%) 12/03/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/15/20 Largest borrow rate increases among liquid names 09/11/20 Largest borrow rate increases among liquid names
Hot Stocks	Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30 03/04/21 03/04 07:30 03/04/21 07:30 DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) , BIIB Biogen $266.84 / -3.2 (-1.19%) Dyne Therapeutics (DYN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/08/21 Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs 01/10/21 Dyne Therapeutics announced new preclinical data from DM1 program 09/28/20 Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' 02/01/21 Biogen announces FDA approval of PLEGRIDY intramuscular administration 01/29/21 Biogen, Eisai announce 3-month extension of review period for aducanumab BLA DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 02/09/21 Dyne Therapeutics initiated with a Buy at JonesTrading 01/07/21 Piper Sandler Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper 10/12/20 Jefferies Dyne Therapeutics initiated with a Buy at Jefferies 10/12/20 JPMorgan Dyne Therapeutics initiated with an Overweight at JPMorgan BIIB Biogen $266.84 / -3.2 (-1.19%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 11/05/20 Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c) BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open 02/02/21 Notable companies reporting before tomorrow's open 21 Jan 17 Sep BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says DYN BIIB DYN Dyne Therapeutics $16.73 / -1.02 (-5.75%) 01/21/21 Fly Intel: Wall Street's top stories for Thursday 01/21/21 Fly Intel: Wall Street's top stories at midday 09/28/20 Fly Intel: After-Hours Movers 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever BIIB Biogen $266.84 / -3.2 (-1.19%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday 03/08/21 Biopharmaceuticals 06/07/21 PDUFA Date for Aducanumab BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 09/15/20 Alexion strength attributed to takeover speculation BIIB BIIB Biogen $266.84 / -3.2 (-1.19%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th
Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Angus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 07:27 Today Argus Regency Centers downgraded to Hold from Buy at Argus 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Initiation	Open Lending initiated with an Outperform at William Blair » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 LPRO Open Lending $38.72 / -1.3 (-3.25%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events Options LPRO Open Lending $38.72 / -1.3 (-3.25%) 01/12/21 Open Lending signs Royal Credit Union to Lenders Protection Program 12/16/20 Open Lending signs Members 1st Federal Credit Union to lenders protection 09/14/20 Open Lending signs Sound Credit Union to Lenders Protection Program LPRO Open Lending $38.72 / -1.3 (-3.25%) 02/10/21 Needham Open Lending initiated with a Buy at Needham 01/20/21 DA Davidson Open Lending price target raised to $45 from $31 at DA Davidson 01/04/21 Deutsche Bank Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank 01/04/21 Stephens Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens 10 Dec 03/09/21 Open Lending - LPRO LPRO Open Lending $38.72 / -1.3 (-3.25%) 10/07/20 Five new option listings on October 7th
Hot Stocks	Hookipa Pharma announces publication on alternating 2-vector cancer therapeutics » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) HOOKIPA Pharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/07/20 Hookipa Pharma reports 'positive' interim Phase 1 data on HB-201 11/30/20 Hookipa Pharma announces Phase 2 interim safety, efficacy results for HB-101 10/29/20 Hookipa Pharma doses first patient in Phase 1/2 trial for HB-202/HB-201 therapy 10/19/20 Hookipa Pharma appoints Jean-Charles Soria to board of directors HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/30/20 JMP Securities Hookipa Pharma price target raised to $25 from $19 at JMP Securities 11/03/20 Fly Intel: Top five analyst initiations 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist 11/03/20 Truist Hookipa Pharma initiated with a Buy at Truist HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 11/12/20 Hookipa Pharma reports Q3 EPS (53c), consensus (43c) 09 Dec HOOK Hookipa Pharma $12.00 / +0.05 (+0.42%) 12/08/20 Fly Intel: After-Hours Movers 03/15/21 Hookipa Pharma - HOOK

Upgrade	Williams upgraded to Outperform from Sector Perform at Scotiabank » 07:29 03/04/21 03/04 07:29 03/04/21 07:29 WMB Williams $23.73 / +0.02 (+0.08%) Scotiabank analyst Alonso… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options WMB Williams $23.73 / +0.02 (+0.08%) 01/26/21 Williams raises quarterly dividend to 41c from 40c 12/17/20 Williams' resolution with Chesapeake receives bankruptcy court approval 11/23/20 Williams announces global resolution with Chesapeake WMB Williams $23.73 / +0.02 (+0.08%) 02/24/21 Mizuho Williams price target raised to $27 from $26 at Mizuho 01/20/21 Mizuho Williams price target raised to $26 from $24 at Mizuho 12/17/20 Credit Suisse Williams upgraded to Outperform from Neutral at Credit Suisse 12/11/20 Morgan Stanley Morgan Stanley upgrades midstream industry view to Attractive, shakes up ratings WMB Williams $23.73 / +0.02 (+0.08%) 02/22/21 Williams sees FY21 adjusted EBITDA of $5.05B-$5.35B 02/22/21 Williams reports Q4 adjusted EPS 31c, consensus 31c 11/02/20 Williams sees 2020 Adjusted EBITDA in lower half of guidance range 11/02/20 Williams reports Q3 adjusted EPS 27c, consensus 27c WMB Williams $23.73 / +0.02 (+0.08%) 10/14/20 Fly Intel: After-Hours Movers WMB Williams $23.73 / +0.02 (+0.08%) 10/09/20 Williams call volume above normal and directionally bullish 10/07/20 Williams put volume heavy and directionally bearish 10/05/20 Unusually active option classes on open October 5th
Hot Stocks	Landos Biopharma says all endpoints in Phase 1 study of NX-13 met » 07:28 03/04/21 03/04 07:28 03/04/21 07:28 LABP Landos Biopharma $15.22 / +0.73 (+5.04%) Landos Biopharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 02/08/21 Landos Biopharma jumps 16% after disclosing insider buys 01/04/21 Landos Biopharma announces results from Phase 2 trial of BT-11 LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 03/01/21 Jefferies Landos Biopharma initiated with a Buy at Jefferies 03/01/21 JPMorgan Landos Biopharma initiated with a Neutral at JPMorgan 03/01/21 Raymond James Landos Biopharma initiated with an Outperform at Raymond James 03/01/21 SVB Leerink Landos Biopharma initiated with an Outperform at SVB Leerink 04 Feb LABP Landos Biopharma $15.22 / +0.73 (+5.04%) 02/07/21 Opening Day: Sana raises largest-ever IPO for preclinical biotech
Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:27 03/04/21 03/04 07:27 03/04/21 07:27 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Jacob… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades 08/19/20 Compass Point Compass Point downgrades Regency Centers on 'tactical valuation call' REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Hot Stocks	NewAge enters LOI to acquire Japan-based Aliven for approx. 1M shares » 07:26 03/04/21 03/04 07:26 03/04/21 07:26 NBEV NewAge $2.82 / -0.1 (-3.43%) NewAge announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge announces $58M private placement 12/01/20 NewAge announces $30M debt facility 11/19/20 NewAge appoints Fred Cooper to board of directors 10/15/20 NewAge's DSD Division on track for double-digit organic growth in 2020 NBEV NewAge $2.82 / -0.1 (-3.43%) 07/21/20 Alliance Global Partners New Age Beverages price target raised to $5 from $3.50 at Alliance Global 04/14/20 Alliance Global Partners New Age Beverages at Alliance Global Partners 03/11/20 Compass Point New Age Beverages price target lowered to $4 from $9 at Compass Point NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge ses Q4 net revenue in $90M range, consensus $79.34M 11/09/20 NewAge reports Q3 EPS (14c), consensus (6c) NBEV NewAge $2.82 / -0.1 (-3.43%) 11/09/20 Fly Intel: Pre-market Movers 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 NewAge - NBEV
Recommendations	Main Street price target raised to $40 from $34 at RBC Capital » 07:25 03/04/21 03/04 07:25 03/04/21 07:25 MAIN Main Street $37.33 / +0.63 (+1.72%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MAIN Main Street $37.33 / +0.63 (+1.72%) 01/20/21 Main Street reports Q4 private loan activity 01/19/21 Capital Southwest supports O2's investment in Flip Electronics 01/07/21 Main Street announces new portfolio investment MAIN Main Street $37.33 / +0.63 (+1.72%) 08/12/20 Truist Main Street price target raised to $33 from $28 at Truist 04/15/20 National Securities Main Street downgraded to Neutral from Buy at National Securities 03/17/20 National Securities Main Street upgraded to Buy from Neutral at National Securities MAIN Main Street $37.33 / +0.63 (+1.72%) 02/25/21 Main Street reports Q4 NII 59c, consensus 51c 11/05/20 Main Street reports Q3 NII 46c, consensus 47c

Recommendations	Exxon Mobil price target raised to $60 from $57 at Morgan Stanley » 07:25 03/04/21 03/04 07:25 03/04/21 07:25 XOM Exxon Mobil $56.52 / +0.45 (+0.80%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil must change direction, not just appoint board candidates, CURE says 03/03/21 Exxon Mobil sees FY21 capital spending $16B-$19B 03/01/21 Michael Angelakis and Jeffrey Ubben join ExxonMobil board 02/24/21 Exxon Mobil to sell U.K. upstream central and northern North Sea assets XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 07:13 Today Truist Exxon Mobil price target raised to $60 from $50 at Truist 06:14 Today Citi Exxon Mobil price target raised to $53 from $44 at Citi 03/02/21 Wells Fargo Exxon Mobil price target raised to $65 from $53 at Wells Fargo 02/26/21 Barclays Exxon Mobil price target raised to $65 from $59 at Barclays XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 02/02/21 Exxon Mobil reports Q4 ex-items EPS 3c, consensus 1c 02/01/21 Notable companies reporting before tomorrow's open 02/01/21 Notable companies reporting before tomorrow's open 12/30/20 Exxon Mobil says Q4 income boosted by up to $600M from gas prices XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/02/21 Exxon CEO says economics, policies creating carbon capture market, Reuters says 03/01/21 Ubben, Angelakis to join board of Exxon Mobil, CNBC reports 02/17/21 Texas prohibits natgas firms from taking fuel out of state, Bloomberg says 02/17/21 Saudis to raise oil output as prices recover, WSJ reports XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/01/21 Fly Intel: Wall Street's top stories for Monday 03/01/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: Pre-market Movers 02/02/21 Fly Intel: Wall Street's top stories for Tuesday XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil call volume above normal and directionally bullish 03/01/21 Unusually active option classes on open March 1st 02/09/21 Unusually active option classes on open February 9th 02/08/21 Exxon Mobil call volume above normal and directionally bullish
Hot Stocks	VBL Therapeutics announces publication of interim analysis of OVAL study » 07:24 03/04/21 03/04 07:24 03/04/21 07:24 VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) VBL Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 03/01/21 VBL Therapeutics announces patient dosing in VB-111 trial 02/22/21 VBL Therapeutics says DSMC recommends continuation of OVAL Phase 3 study 01/27/21 VBL Therapeutics doses first patient in Phase 2 study of VB-201 01/15/21 VBL Therapeutics enters into share purchase agreement with Aspire Capital VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 01/28/21 H.C. Wainwright VBL Therapeutics price target raised to $4 from $3 at H.C. Wainwright VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 11/16/20 VBL Therapeutics reports Q3 EPS (12c), consensus (13c) VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 12/30/20 Fly Intel: After-Hours Movers 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 31st Annual Healthcare Virtual Conference
Hot Stocks	Fulcrum Therapeutics CEO Robert Gould to retire, Bryan Stuart to succeed » 07:23 03/04/21 03/04 07:23 03/04/21 07:23 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) Fulcrum Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:16 Today Fulcrum Therapeutics expects cash to fund requirements into 4Q22 07:16 Today Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Recommendations	General Electric price target raised to $17 from $13 at Morgan Stanley » 07:22 03/04/21 03/04 07:22 03/04/21 07:22 GE General Electric $13.45 / +0.48 (+3.70%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GE General Electric $13.45 / +0.48 (+3.70%) 02/24/21 Altair acquires Flow Simulator sofftware from GE Aviation 02/17/21 General Electric focusing on growing through existing business lines, CEO says 02/17/21 General Electric CEO says unlikely to do large M&A deals soon 02/12/21 Trian Fund exits nVent, increases stake in GE GE General Electric $13.45 / +0.48 (+3.70%) 03/02/21 Barclays Danaher started at Overweight at Barclays on GE biopharma business potential 02/22/21 Goldman Sachs General Electric price target raised to $15 at Goldman Sachs after meetings 01/28/21 Barclays General Electric price target raised to $13 from $12 at Barclays 01/27/21 Morgan Stanley General Electric price target raised to $13 from $12 at Morgan Stanley GE General Electric $13.45 / +0.48 (+3.70%) 01/26/21 General Electric sees FY21 adjusted EPS 15c-25c, consensus 38c 01/26/21 General Electric reports Q4 adjusted EPS 8c, consensus 9c 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open GE General Electric $13.45 / +0.48 (+3.70%) 02/16/21 General Electric sees negative cash flow in Q1, Reuters reports 02/11/21 Southwest in talks for at least 300 new 150-seat planes, Air Current says 01/14/21 GE says Siemens stole trade secrets in bid to rig contracts , Reuters reports 01/11/21 GE to pause donations to lawmakers who voted against Biden win, Bloomberg says GE General Electric $13.45 / +0.48 (+3.70%) 01/27/21 Nokia soars but company 'not aware' of apparent reason for trading activity 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Pre-market Movers 11/24/20 Target upgrade, Microsoft initiation among today's top calls on Wall Street 03/10/21 General Electric Co. GE General Electric $13.45 / +0.48 (+3.70%) 02/24/21 General Electric call volume above normal and directionally bullish 01/26/21 Early notable gainers among liquid option names on January 26th 01/06/21 General Electric call volume above normal and directionally bullish 12/23/20 Notable open interest changes for December 23rd
Hot Stocks	DeepGreen Metals enters $2.9B combination agreement with SOAC » 07:22 03/04/21 03/04 07:22 03/04/21 07:22 SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) DeepGreen Metals … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Periodicals Options SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) 02/23/21 DeepGreen Metals in talks to become public through SOAC merger, Bloomberg says SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) 03/02/21 Sustainable Opportunities Acquisition Corp (Class A Stock) call volume above normal and directionally bullish

Hot Stocks	Kronos Bio to initiate Phase 3 trial of entospletinib in mid-2021 » 07:21 03/04/21 03/04 07:21 03/04/21 07:21 KRON Kronos Bio $28.75 / -0.66 (-2.24%) Kronos Bio announced,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options KRON Kronos Bio $28.75 / -0.66 (-2.24%) 02/25/21 Kronos Bio announces first patient dosed in Phase 1/2 KB-0742 trial 01/26/21 Kronos Bio appoints Marianne De Backer to board of directors 12/08/20 Kronos Bio appoints Pasit Phiasivongsa as SVP, pharmaceutical development 12/07/20 Kronos Bio announces FDA clearance of IND application for KB-0742 KRON Kronos Bio $28.75 / -0.66 (-2.24%) 11/03/20 Fly Intel: Top five analyst initiations 11/03/20 Jefferies Kronos Bio initiated with a Buy at Jefferies 11/03/20 Piper Sandler Kronos Bio initiated with an Overweight at Piper Sandler 11/03/20 Goldman Sachs Kronos Bio initiated with a Buy at Goldman Sachs KRON Kronos Bio $28.75 / -0.66 (-2.24%) 11/18/20 Kronos Bio reports Q3 EPS ($6.48), consensus ($1.47) 09 Oct KRON Kronos Bio $28.75 / -0.66 (-2.24%) 10/11/20 Opening Day: iHuman makes trading debut amid U.S.-China tensions KRON Kronos Bio $28.75 / -0.66 (-2.24%) 01/28/21 new option listings on January 28th
Hot Stocks	Sol-Gel Technologies expects cash to fund requirements into 3Q22 » 07:20 03/04/21 03/04 07:20 03/04/21 07:20 SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) As of December 31, 2020,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 12/07/20 Sol-Gel Technologies announces FDA acceptance of NDA filing for Twyneo 11/12/20 Sol-Gel Technologies expects cash to fund operations into 3Q21 09/10/20 Sol-Gel Technologies NDA for Epsolay accepted for filing by FDA SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 03/26/20 H.C. Wainwright Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 07:19 Today Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) 11/12/20 Sol-Gel Technologies reports Q3 EPS (37c), consensus (46c) SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 09/11/20 Fly Intel: Pre-market Movers
Hot Stocks	Shift4 Payments announces acquisition of VenueNext, terms undisclosed » 07:19 03/04/21 03/04 07:19 03/04/21 07:19 FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) Shift4 Payments announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 01/07/21 Shift4 Payments, Sightline Payments announce strategic parntership 12/01/20 Shift4 Payments falls -7.8% 11/05/20 Shift4 Payments acquires 3dcart ecommerce platform, terms not disclosed 10/14/20 Shift4 Payments sees Q3 payment volume $7.0B-$7.1B FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 01/06/21 Wolfe Research Shift4 Payments downgraded to Peer Perform from Outperform at Wolfe Research 01/06/21 BofA Shift4 Payments double-downgraded to Underperform from Buy at BofA 12/21/20 Fly Intel: Top five analyst initiations 12/21/20 Piper Sandler Shift4 Payments initiated with an Overweight at Piper Sandler FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 07:09 Today Shift4 Payments sees FY21 revenue $1.1B-$1.2B, consensus $1.08B 07:06 Today Shift4 Payments reports Q4 adjusted EPS (5c), consensus 2c 11/05/20 Shift4 Payments reports Q3 EPS (12c), consensus 5c 11/04/20 Notable companies reporting before tomorrow's open 03 Dec 11 Sep 05 Jun FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 11/30/20 Fly Intel: After-Hours Movers 11/05/20 Fly Intel: Pre-market Movers 08:30 Today Shift4 Payments - FOUR FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 12/14/20 Largest borrow rate increases among liquid names
Earnings	Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) » 07:19 03/04/21 03/04 07:19 03/04/21 07:19 SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) Reports 2020 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 12/07/20 Sol-Gel Technologies announces FDA acceptance of NDA filing for Twyneo 11/12/20 Sol-Gel Technologies expects cash to fund operations into 3Q21 09/10/20 Sol-Gel Technologies NDA for Epsolay accepted for filing by FDA SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 03/26/20 H.C. Wainwright Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 11/12/20 Sol-Gel Technologies reports Q3 EPS (37c), consensus (46c) SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 09/11/20 Fly Intel: Pre-market Movers
Downgrade	Retail Properties of America downgraded to Sector Weight at KeyBanc » 07:18 03/04/21 03/04 07:18 03/04/21 07:18 RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 12/08/20 Retail Properties of America raises quarterly dividend to 6c from 5c per share 09/08/20 Retail Properties of America resumes dividend payment and provides update RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 05:20 Today KeyBanc Retail Properties downgraded to Sector Weight from Overweight at KeyBanc 12/15/20 Citi Retail Properties of America price target raised to $9.50 from $7 at Citi 11/10/20 Compass Point Compass Point upgrades four retail REITs to Neutral after Pfizer 'game changer' 11/09/20 Compass Point Retail Properties of America upgraded to Neutral from Sell at Compass Point RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 02/16/21 Retail Properties of America sees FY21 operating FFO 76c-84c 02/16/21 Retail Properties of America reports Q4 operating FFO 20c, consensus 21c 11/02/20 Retail Properties of America reports Q3 operating FFO 21, consensus 20c 05/05/21 Retail Properties of America - RPAI

Hot Stocks	Fulcrum Therapeutics expects cash to fund requirements into 4Q22 » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) The company said,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:16 Today Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Upgrade	Site Centers upgraded to Overweight at KeyBanc » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 SITC Site Centers $12.89 / +0.1 (+0.78%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events SITC Site Centers $12.89 / +0.1 (+0.78%) 01/12/21 Site Centers provides Q4 operational update SITC Site Centers $12.89 / +0.1 (+0.78%) 05:19 Today KeyBanc Site Centers upgraded to Overweight from Sector Weight at KeyBanc 02/23/21 Mizuho Site Centers price target raised to $13 from $10.50 at Mizuho 01/14/21 Piper Sandler Site Centers upgraded to Overweight from Neutral at Piper Sandler 12/15/20 Citi Site Centers price target raised to $11 from $8.50 at Citi SITC Site Centers $12.89 / +0.1 (+0.78%) 02/18/21 Site Centers sees 2021 operating FFO 90c-$1.00, consensus 98c 02/18/21 Site Centers reports Q4 operating FFO 25c, consensus 24c 10/27/20 Site Centers reports Q3 operating FFO 23c, consensus 23c 02 Mar 03/17/21 Site Centers
Hot Stocks	Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) After careful… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program 11/10/20 Fulcrum Therapeutics: Curtis Oltmans to join as general counsel FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Initiation	Wheaton Precious Metals initiated with an Overweight at JPMorgan » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) JPMorgan analyst Tyler… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/10/21 Wheaton Precious Metals sees 2021 production 720K-780K gold eq. oz. 02/01/21 Silver producers up in pre-market on r/wallstreetbets short squeeze speculation 12/11/20 Wheaton Precious Metals to acquire Mexico silver stream from Capstone for $150M 11/09/20 Wheaton Precious Metals raises quarterly dividend 20% to 12c per share WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 03/01/21 Berenberg Wheaton Precious Metals price target raised to 3,700 GBp at Berenberg 02/16/21 Berenberg Wheaton Precious Metals price target lowered to 3,500 GBp from 3,700 GBp at Berenberg 02/08/21 Stifel Wheaton Precious Metals upgraded to Buy from Hold at Stifel 02/02/21 Credit Suisse Wheaton Precious Metals price target lowered to C$62 from C$64 at Credit Suisse WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 11/09/20 Wheaton Precious Metals reports Q3 EPS 33c, consensus 33c WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/01/21 CME raises Silver futures margins by 18% to curb volatility, Bloomberg says WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/01/21 Fly Intel: Wall Street's top stories for Monday 02/01/21 Fly Intel: Wall Street's top stories at midday 03/12/21 Wheaton Precious Metals - WPM WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/17/21 Wheaton Precious Metals call volume above normal and directionally bullish 01/28/21 Wheaton Precious Metals call volume above normal and directionally bullish 01/28/21 Largest borrow rate increases among liquid names 12/09/20 Largest borrow rate increases among liquid names
Earnings	Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) » 07:15 03/04/21 03/04 07:15 03/04/21 07:15 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) Reports Q4 revenue $4.2M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program 11/10/20 Fulcrum Therapeutics: Curtis Oltmans to join as general counsel FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC

Events

Earnings calls, analyst events, roadshows and more

BALY
Today at 08:00

Bally's - BALY Conference Calls
ATC
Today at 08:00

Atotech - ATC Conference Calls
WVE
Today at 08:00

Wave Life Sciences - WVE Conference Calls
FULC
Today at 08:00

Fulcrum Therapeutics - FULC Conference Calls
HCM
Today at 08:00

Hutchison China MediTech - HCM Conference Calls
Today at 08:00

Consumer Data Analytics Industry Meetings
Today at 08:30

Productivity & Costs: Non-farm Poductivity Annual Rate: Q4(r):2020 Government Event
Today at 08:30

Productivity and Costs: Unit Labor Costs Annual Rate: Q4(r):2020 Government Event
Today at 08:30

Initial Jobless Claims Level: Week 2/27/2021 Government Event
Today at 08:30

Initial Jobless Claims Change: Week 2/27/2021 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson Priced at: $41.00 4.95M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DGII X DGII Digi International Secondary Managers: Piper Sandler Priced at: $19.50 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities Priced at: $18.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	EYE X EYE National Vision Block Trade Managers: JPMorgan $46.50-47.00 3.9M Shares AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LASR X LASR nLight Spot Secondary Managers: Stifel & Raymond James $34.00-35.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR $11.50-11.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STX X STX Seagate Spot Secondary Managers: JPMorgan $75.94 4.65M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Digital Turbine price target raised to $70 from $42 at Roth Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access